Latest news with #NuSkin
Business Wire
02-06-2025
- Business
- Business Wire
Nu Skin Enterprises Appoints James Winett to Board of Directors
PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises (NUS: NYSE) today announced the appointment of James Winett, a managing member of SIZE Advisory Group, to the company's board of directors. He was elected by shareholders at the annual shareholder meeting for Nu Skin Enterprises. 'Jim adds extensive expertise in strategic planning, operations and finance from his many years of consulting experience,' said Steven J. Lund, executive chairman of the board. 'He will also be an asset to our Rhyz businesses with his background in corporate transactions and advising small businesses and start-ups. We welcome Jim to the board and look forward to tapping into his insights and experience.' Winett is a managing member of SIZE Advisory Group, a full-service business advisory firm he co-founded in 2020. At SIZE he provides consulting services to companies ranging from early-stage start-ups to large enterprises. Prior to SIZE, Winett was a consultant at other firms that he founded, including DPAA Group, Inc., where he served as a managing member from 2014 to 2023. Winett began his career at Price Waterhouse LLP, where he served in both the audit and assurance group and the corporate recovery and business turnaround services group. Winett received an MBA from Northwestern University's Kellogg School of Management and a bachelor of science degree in accountancy from the University of Illinois at Urbana-Champaign. About Nu Skin Enterprises The Nu Skin Enterprises Inc. (NYSE: NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.
Business Wire
08-05-2025
- Business
- Business Wire
Nu Skin Enterprises Reports First Quarter Revenue at High End of Guidance
PROVO, Utah--(BUSINESS WIRE)--Nu Skin Enterprises Inc. (NYSE: NUS) today announced first quarter revenue at the high end of its guidance range. Executive Summary Q1 2025 vs. Prior-year Quarter 'We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year,' said Ryan Napierski, Nu Skin president and CEO. 'We drove year-over-year growth in Latin America and our Rhyz manufacturing segment, but we continue to experience consumer caution in premium beauty due to concerns such as inflation and tariffs in many parts of the world. Through 2025, we remain focused on building on our recent product launches and preparing for the preview of our Prysm iO intelligent wellness device in the back half of the year. This palm-sized device provides real-time insights into a customer's health, informing recommendations for product subscriptions and increasing customer satisfaction and loyalty. We are also laying the groundwork for expansion into India with a market pre-opening in Q4 and formal launch in mid-2026 and prioritizing our efforts to continue improving margins across the board.' Q1 2025 Year-over-year Operating Results Revenue $364.5 million compared to $417.3 million (3.0)% FX impact or $(12.3) million Gross Margin 67.8% compared to 70.5% Nu Skin business was 76.7% compared to 76.9% Selling Expenses 32.5% compared to 36.8% Nu Skin business was 38.7% compared to 41.7% G&A Expenses 31.1% or 28.9% excluding certain charges compared to 29.9% Restructuring and Impairment Expenses $25.1 million impairment compared to $7.3 million restructuring charges Operating Margin (2.7)% or 6.4% excluding impairment and other charges compared to 2.1% or 3.8% excluding restructuring charges Interest Expense $3.3 million compared to $7.3 million Gain on Sale of Business $176.2 million gain on sale of Mavely Other Expense $28.4 million compared to $0.4 million Reflects $28.1 million unrealized loss on investment Income Tax Rate 20.1% or 41.9% excluding Mavely gain and other charges compared to 148.4% or 48.5% excluding restructuring charges EPS $2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges Expand Stockholder Value Dividend Payments $3.0 million Stock Repurchases $5.0 million $157.4 million remaining in authorization Expand Q2 and Full-year 2025 Outlook Q2 2025 Revenue $355 to $390 million; (19)% to (11)% or (17)% to (9)% excluding Mavely 2024 revenue Approximately (3) to (2)% FX impact Q2 2025 EPS $0.20 to $0.30 2025 Revenue $1.48 to $1.62 billion; (15)% to (6)% or (11)% to (3)% excluding Mavely 2024 revenue Approximately (3)% FX impact 2025 EPS $2.80 to $3.20 or $0.90 to $1.30 excluding Mavely gain and other charges Expand 'In addition to delivering on revenue and adjusted earnings, we saw encouraging improvement in core Nu Skin operating margin, driven by ongoing cost efficiency initiatives across every segment,' said James D. Thomas, chief financial officer. 'We also made meaningful progress in strengthening our balance sheet by reducing outstanding debt by $155 million, achieving our lowest debt level in more than 10 years. In addition, we returned $8 million to shareholders — $3 million in the form of dividends and $5 million via share repurchases. While macroeconomic uncertainty around trade tensions and tariffs continues to impact visibility, we are maintaining our adjusted annual guidance as we closely monitor developments throughout the remainder of 2025. For the second quarter, we project revenue between $355 million and $390 million, with earnings per share in the range of $0.20 to $0.30.' Conference Call The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at A replay of the webcast will be available on the same page through May 22, 2025. About Nu Skin Enterprises Inc. The Nu Skin Enterprises Inc. (NYSE: NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories. Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are 'forward-looking statements' for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the macro environment and the company's performance, growth and growth opportunities, shareholder value, product previews and launches, investments, initiatives, and new market expansion; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as 'believe,' 'expect,' 'anticipate,' 'accelerate,' 'project,' 'vision,' 'remain,' 'continue,' 'outlook,' 'guidance,' 'improve,' 'will,' 'would,' 'could,' 'may,' 'might,' the negative of these words and other similar words. The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following: any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis; risk that direct selling laws and regulations in any of the company's markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company's business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events; economic conditions and events globally; the company's future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company's products imported into the company's markets, and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; competitive pressures in the company's markets; risk that epidemics or other crises, as well as any related disruptions, could negatively impact our business; adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others; political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets; uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results; risk of foreign-currency fluctuations and the currency translation impact on the company's business associated with these fluctuations; uncertainties regarding the future financial performance of the businesses the company has acquired; risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies; and regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements. The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law. Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period's revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company's revenue from period to period. Earnings per share, general & administrative expenses, operating margin and income tax rate, each excluding the gain from the Mavely sale, restructuring charges, impairment charges, and/or other charges, as well as revenue growth rate excluding Mavely 2024 revenue, also are non-GAAP financial measures. Restructuring charges and impairment charges are not part of the ongoing operations of our underlying business; Mavely revenue is no longer included in our operations following our sale of this business on January 2, 2025; and the gain from the Mavely sale and the other charges incurred in connection with this sale that have been excluded in the non-GAAP financial measures are not typical for our ongoing operations. The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these items facilitates period-to-period comparisons of the company's performance. Please see the reconciliations of these items to our earnings per share, general & administrative expenses, operating margin, income tax rate and revenue growth rate calculated under GAAP, below. The following table sets forth revenue for the three-month periods ended March 31, 2025, and 2024 for each of our reportable segments (U.S. dollars in thousands): The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended March 31, 2025, and 2024: Three Months Ended March 31, 2025 2024 Change Customers Americas 227,514 199,399 14% Southeast Asia/Pacific 74,584 93,411 (20)% Mainland China 122,474 162,239 (25)% Japan 107,742 108,808 (1)% Europe & Africa 130,154 163,481 (20)% South Korea 71,721 100,230 (28)% Hong Kong/Taiwan 42,523 47,693 (11)% Total Customers 776,712 875,261 (11)% Paid Affiliates Americas 26,936 29,081 (7)% Southeast Asia/Pacific 22,296 29,778 (25)% Mainland China 19,859 24,405 (19)% Japan 21,073 21,679 (3)% Europe & Africa 15,184 18,313 (17)% South Korea 16,548 20,594 (20)% Hong Kong/Taiwan 9,622 10,321 (7)% Total Paid Affiliates 131,518 154,171 (15)% Sales Leaders Americas 6,174 6,616 (7)% Southeast Asia/Pacific 4,542 5,570 (18)% Mainland China 6,214 9,600 (35)% Japan 6,210 6,385 (3)% Europe & Africa 2,839 3,715 (24)% South Korea 2,850 4,122 (31)% Hong Kong/Taiwan 2,207 2,601 (15)% Total Sales Leaders 31,036 38,609 (20)% Expand 'Customers' are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force. 'Paid Affiliates' are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as 'Brand Affiliates' because their primary role is to promote our brand and products through their personal social networks. 'Sales Leaders' are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter. NU SKIN ENTERPRISES, INC. Consolidated Balance Sheets (Unaudited) (U.S. dollars in thousands) March 31, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 203,770 $ 186,883 Current investments 9,781 11,111 Accounts receivable, net 56,576 50,784 Inventories, net 188,776 190,242 Prepaid expenses and other 65,954 72,643 Current assets held for sale — 26,936 Total current assets 524,857 538,599 Property and equipment, net 380,067 379,595 Operating lease right-of-use assets 79,389 72,605 Goodwill 83,625 83,625 Other intangible assets, net 47,554 74,278 Other assets 275,919 298,008 Long-term assets held for sale — 22,204 Total assets $ 1,391,411 $ 1,468,914 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 33,590 $ 34,880 Accrued expenses 206,710 217,808 Current portion of long-term debt 20,000 30,000 Current liabilities held for sale — 13,919 Total current liabilities 260,300 296,607 Operating lease liabilities 61,949 58,439 Long-term debt 218,757 363,613 Other liabilities 96,436 97,475 Long-term liabilities held for sale — 1,325 Total liabilities 637,442 817,459 Commitments and contingencies Stockholders' equity: Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued 91 91 Additional paid-in capital 623,477 627,787 Treasury stock, at cost – 41.2 million and 40.8 million shares (1,562,211) (1,563,614) Accumulated other comprehensive loss (123,850) (124,758) Retained earnings 1,8416,462 1,711,949 Total stockholders' equity 753,969 651,455 Total liabilities and stockholders' equity $ 1,391,411 $ 1,468,914 Expand NU SKIN ENTERPRISES, INC. Reconciliation of General and Administrative Expenses Excluding Certain Charges to GAAP General and Administrative Expenses (in thousands, except for per share amounts) Three months ended March 31, 2025 2024 General and administrative expenses $ 113,204 $ 124,566 Impact of other charges (1) (7,966) - Adjusted general and administrative expenses $ 105,238 $ 124,566 General and administrative expenses as a percentage of revenue 31.1% 29.9% General and administrative expenses as a percentage of revenue, excluding certain charges 28.9% 29.9% Revenue $ 364,490 $ 417,306 __________________________ (1) Other charges for the first quarter of 2025 consist of expenses incurred in connection with the Mavely sale, including $2.7 million of transaction bonuses for certain employees and $5.2 million of equity compensation as a result of the vesting of the Mavely profits interest units. Expand NU SKIN ENTERPRISES, INC. (in thousands, except for per share amounts) Three months ended March 31, 2025 2024 Provision for income taxes $ 27,086 $ 1,634 Impact of other charges (1) on provision for income taxes 725 - Impact of restructuring and impairment on provision for income taxes 5,433 2,356 Impact of gain on Mavely sale on provision for income taxes (31,104) Impact of unrealized investment loss on provision for income taxes 6,074 - Provision for income taxes, excluding impact of Mavely gain and certain charges $ 8,214 $ 3,990 Income before provision for income taxes 134,601 1,101 Impact of other charges (1) 7,966 - Impact of restructuring and impairment expense: 25,114 7,134 Impact of gain on Mavely sale (176,162) - Impact of unrealized investment loss 28,077 - $ 19,596 $ 8,235 Effective tax rate 20.1% 148.4% Effective tax rate, excluding impact of certain charges 41.9% 48.5% Expand NU SKIN ENTERPRISES, INC. Reconciliation of Earnings Per Share Excluding Impact of Mavely Gain and Certain Charges to GAAP Earnings Per Share (in thousands, except for per share amounts) Three months ended March 31, 2025 2024 Net income (loss) $ 107,515 $ (533) Impact of other charges Other charges (1) 7,966 - Tax impact (725) - Impact of restructuring and impairment expense: Restructuring and impairment 25,114 7,134 Tax impact (5,433) (2,356) Impact of gain on Mavely sale Gain on Mavely sale (176,162) - Tax impact 31,104 - Impact of unrealized investment loss Unrealized investment loss 28,077 - Tax impact (6,074) - Adjusted net income $ 11,382 $ 4,245 Diluted earnings per share $ 2.14 $ (0.01) Diluted earnings per share, excluding restructuring impact $ 0.23 $ 0.09 Weighted-average common shares outstanding (000) 50,328 49,538 Expand Year ended December 31, 2025 Low end High end Earnings Per Share $ 2.80 $ 3.20 Impact of other charges Other charges (1) 0.16 0.16 Tax impact (0.01) (0.01) Impact of restructuring and impairment expense: Restructuring and impairment 0.50 0.50 Tax impact (0.11) (0.11) Impact of gain on Mavely sale Gain on Mavely sale (3.50) (3.50) Tax impact 0.62 0.62 Impact of unrealized investment loss Unrealized investment loss 0.56 0.56 Tax impact (0.12) (0.12) Adjusted EPS $ 0.90 $ 1.30 Expand
Yahoo
07-05-2025
- Business
- Yahoo
Earnings To Watch: Nu Skin (NUS) Reports Q1 Results Tomorrow
Personal care company Nu Skin (NYSE:NUS) will be announcing earnings results tomorrow afternoon. Here's what to expect. Nu Skin beat analysts' revenue expectations by 2.2% last quarter, reporting revenues of $445.6 million, down 8.8% year on year. It was a slower quarter for the company, with revenue guidance for next quarter missing analysts' expectations and a significant miss of analysts' gross margin estimates. Is Nu Skin a buy or sell going into earnings? Read our full analysis here, it's free. Nu Skin Total Revenue Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Nu Skin has missed Wall Street's revenue estimates four times over the last two years. Looking at Nu Skin's peers in the personal care segment, some have already reported their Q1 results, giving us a hint as to what we can expect. USANA delivered year-on-year revenue growth of 9.5%, beating analysts' expectations by 2.7%, and Estée Lauder reported a revenue decline of 9.9%, topping estimates by 1.2%. USANA traded up 5.2% following the results while Estée Lauder's stock price was unchanged. Read our full analysis of USANA's results here and Estée Lauder's results here. There has been positive sentiment among investors in the personal care segment, with share prices up 4.9% on average over the last month. Nu Skin is down 4% during the same time. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Yahoo
24-04-2025
- Business
- Yahoo
2 Small-Cap Stocks on Our Watchlist and 1 to Brush Off
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors. These trade-offs can cause headaches for even the most seasoned professionals, which is why we started StockStory - to help you separate the good companies from the bad. Keeping that in mind, here are two small-cap stocks that could be the next big thing and one that could be down big. Market Cap: $272.7 million With person-to-person marketing and sales rather than selling through retail stores, Nu Skin (NYSE:NUS) is a personal care and dietary supplements company that engages in direct selling. Why Is NUS Not Exciting? Annual revenue declines of 13.7% over the last three years indicate problems with its market positioning Overall productivity fell over the last year as its plummeting sales were accompanied by a decline in its operating margin Earnings per share decreased by more than its revenue over the last three years, showing each sale was less profitable At $5.63 per share, Nu Skin trades at 5.2x forward price-to-earnings. Read our free research report to see why you should think twice about including NUS in your portfolio, it's free. Market Cap: $5.77 billion With its technology playing a key role in the massive 1.2 gigawatt Noor Abu Dabhi solar farm project, Nextracker (NASDAQ:NXT) is a provider of solar tracker systems that help solar panels follow the sun. Why Are We Bullish on NXT? Sales pipeline is in good shape as its backlog averaged 56.1% growth over the past two years Free cash flow margin jumped by 13.1 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends Returns on capital are growing as management capitalizes on its market opportunities Nextracker's stock price of $39.94 implies a valuation ratio of 12.3x forward price-to-earnings. Is now a good time to buy? Find out in our full research report, it's free. Market Cap: $3.51 billion Founded in 2013 with a mission to transform healthcare for seniors, Alignment Healthcare (NASDAQ:ALHC) provides Medicare Advantage health plans for seniors with features like concierge services, transportation benefits, and technology-driven care coordination. Why Are We Positive On ALHC? Average customer growth of 36.9% over the past two years demonstrates success in acquiring new clients that could increase their spending in the future Notable projected revenue growth of 38.6% for the next 12 months hints at market share gains Adjusted operating margin improvement of 2.1 percentage points over the last two years demonstrates its ability to scale efficiently Alignment Healthcare is trading at $18.15 per share, or 83.3x forward EV-to-EBITDA. Is now the time to initiate a position? See for yourself in our full research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Sterling Infrastructure (+1,096% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Yahoo
15-04-2025
- Business
- Yahoo
Winners And Losers Of Q4: Nu Skin (NYSE:NUS) Vs The Rest Of The Personal Care Stocks
As the Q4 earnings season comes to a close, it's time to take stock of this quarter's best and worst performers in the personal care industry, including Nu Skin (NYSE:NUS) and its peers. While personal care products products may seem more discretionary than food, consumers tend to maintain or even boost their spending on the category during tough times. This phenomenon is known as "the lipstick effect" by economists, which states that consumers still want some semblance of affordable luxuries like beauty and wellness when the economy is sputtering. Consumer tastes are constantly changing, and personal care companies are currently responding to the public's increased desire for ethically produced goods by featuring natural ingredients in their products. The 13 personal care stocks we track reported a satisfactory Q4. As a group, revenues beat analysts' consensus estimates by 3.7% while next quarter's revenue guidance was 7% below. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 17.4% since the latest earnings results. With person-to-person marketing and sales rather than selling through retail stores, Nu Skin (NYSE:NUS) is a personal care and dietary supplements company that engages in direct selling. Nu Skin reported revenues of $445.6 million, down 8.8% year on year. This print exceeded analysts' expectations by 2.2%. Despite the top-line beat, it was still a slower quarter for the company with revenue guidance for next quarter missing analysts' expectations and a significant miss of analysts' gross margin estimates. The stock is down 5% since reporting and currently trades at $6.09. Read our full report on Nu Skin here, it's free. Rising to fame on TikTok because of its 'bond building" hair products, Olaplex (NASDAQ:OLPX) offers products and treatments that repair the damage caused by traditional heat and chemical-based styling goods. Olaplex reported revenues of $100.7 million, down 9.8% year on year, outperforming analysts' expectations by 14.4%. The business had an incredible quarter with an impressive beat of analysts' EPS estimates and a solid beat of analysts' EBITDA estimates. Olaplex achieved the biggest analyst estimates beat and highest full-year guidance raise among its peers. The stock is down 7.3% since reporting. It currently trades at $1.27. Is now the time to buy Olaplex? Access our full analysis of the earnings results here, it's free. With a portfolio boasting many household brands, Coty (NYSE:COTY) is a beauty products powerhouse spanning cosmetics, fragrances, and skincare. Coty reported revenues of $1.67 billion, down 3.3% year on year, falling short of analysts' expectations by 3.1%. It was a softer quarter as it posted a significant miss of analysts' EPS estimates and a miss of analysts' organic revenue estimates. Coty delivered the weakest performance against analyst estimates in the group. As expected, the stock is down 23.3% since the results and currently trades at $5.19. Read our full analysis of Coty's results here. Co-founded by actress Jessica Alba, The Honest Company (NASDAQ:HNST) sells diapers and wipes, skin care products, and household cleaning products. The Honest Company reported revenues of $99.84 million, up 10.6% year on year. This print beat analysts' expectations by 3.1%. Overall, it was a stunning quarter as it also produced an impressive beat of analysts' EPS estimates and a solid beat of analysts' EBITDA estimates. The stock is down 11.3% since reporting and currently trades at $5.04. Read our full, actionable report on The Honest Company here, it's free. Named after its founder, who was an entrepreneurial woman from New York with a passion for skincare, Estée Lauder (NYSE:EL) is a one-stop beauty shop with products in skincare, fragrance, makeup, sun protection, and men's grooming. Estée Lauder reported revenues of $4.00 billion, down 6.4% year on year. This result topped analysts' expectations by 0.7%. It was a strong quarter as it also logged an impressive beat of analysts' EPS estimates and a solid beat of analysts' EBITDA estimates. The stock is down 32.4% since reporting and currently trades at $55.99. Read our full, actionable report on Estée Lauder here, it's free. In response to the Fed's rate hikes in 2022 and 2023, inflation has been gradually trending down from its post-pandemic peak, trending closer to the Fed's 2% target. Despite higher borrowing costs, the economy has avoided flashing recessionary signals. This is the much-desired soft landing that many investors hoped for. The recent rate cuts (0.5% in September and 0.25% in November 2024) have bolstered the stock market, making 2024 a strong year for equities. Donald Trump's presidential win in November sparked additional market gains, sending indices to record highs in the days following his victory. However, debates continue over possible tariffs and corporate tax adjustments, raising questions about economic stability in 2025. Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Sign in to access your portfolio
